Brexit could lead to more Swedish AstraZeneca jobs

On Friday, AstraZeneca presented its full-year and fourth quarter 2017 earnings report. Despite a couple of percent decrease in revenue, Jan-Olof Jacke, CEO of AstraZeneca Sweden, told Göteborgs-Posten that the final quarter of 2017 bodes well for the future.

On the same day, Pam Cheng, head of production at AstraZeneca, stated in an interview with Dagens Nyheter thatthe additional costs resulting from Brexit will lead to more jobs in Sweden. The company has already decided to duplicate the quality testing of medicines in Sweden, and Pam Cheng does not rule out the possibility of more jobs.

– “Brexit is one of many examples of how our competitiveness can be tested at any time,” says Helena Strigård, Head of Policy at SwedenBIO. And then we need to stand our ground and maintain a high, consistent level – not least when it comes to access to expertise, which seems to have been important in this case.